A Prospective Validation Cohort Study of a Prediction System on nSLN Metastasis in Early Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

388 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-10-15

Study Completion Date

2020-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the previous study, the investigator established a predictive model for non-sentinel lymph node involvement in early breast cancer (cT1-2cN0, 1-2 SLNs involvement). To validation the clinical value of the model, the investigator design a prospectively research using the model guiding for further axillary lymph node dissection in SLN-positve early breast cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prone Positioning CT Scan and Ultrasound Assessing Axillary Lymph Nodes in Patients With Breast Cancer Official Title: Evaluation of Axillary Lymph Nodes Using Prone Positioning Computed Tomography Scan and Ultrasound in Patients With Breast Cancer

NCT05346510

Breast Cancer

RECRUITING NA

The Association Between Axillary Lymph Node Metastasis Patterns and Breast Cancer Prognosis

NCT07283718

Breast Cancer Invasive

ACTIVE_NOT_RECRUITING

Medico-economic Study of Three Strategies of Sentinel Lymph Node Analysis in Operable Breast Cancer

NCT02056886

Breast Cancer Surgery

COMPLETED NA

Axillary Lymph Node Treatment Guided by Naocarbon Tracing After Neoadjuvant Chemotherapy

NCT05241119

Breast Cancer

RECRUITING NA

Evaluation Of Lymph Nodes After Neoadjuvant Chemotherapy

NCT02752009

Breast Cancer

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the previous study, a predictive model for non-sentinel lymph node involvement in early breast cancer (cT1-2cN0, 1-2 SLNs involvement) was established. This model was designed for predicting the status of non-sentinel lymph node in cT1-2cN0 with 1-2 SLNs involvement breast cancer based on peripheral blood CK19 and contrast-enhanced ultrasound. The investigator previously tested this model comparing with MSKCC model in a same population and confirmed a result of satisfactory low false-negative rate and high AUC. This model had a potential practise value in clinic applying. For further validation, the research group design the CK19B trial to prospectively using this model in decision strategy of whether receiving ALND in 1-2SLNs+ patients. If the model predictive result is negative, the risk of nSLNs involvement is estimated very low and the patients should be avoid ALND, even radiotherapy no matter the surgery is mastectomy or conserving. If the model result is positive, then further ALND or radiotherapy should be accepted by patients to decrease the risk of local and regional recurrent. A prospectively and conditional grouping method is planned for this cohort study. The primary endpoint is disease-free survival (DFS) in two groups, the second primary endpoint is local recurrent rate (LRR) and overall survival (OS).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymph Node Metastases Breast Cancer Predictive Cancer Model

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

This study based on prospective cohort method and concerning on the two groups (whether ALND or not) by predictive model nSLN results.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

predictive nSLN-

No further axillary lymph node dissection (ALND)

Group Type NO_INTERVENTION

No interventions assigned to this group

predictive nSLN+

axillary lymph node dissection (ALND)

Group Type ACTIVE_COMPARATOR

axillary lymph node dissection (ALND)

Intervention Type PROCEDURE

If the patients had predictive nSLN+, need further axillary lymph node dissection.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

axillary lymph node dissection (ALND)

If the patients had predictive nSLN+, need further axillary lymph node dissection.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

the test group should be in accordance with the pathological diagnosis of breast cancer, the clinical stage of breast cancer (stage cTis, cI, cII and cT3N1M0), the initial treatment to receive surgical treatment. Complete preoperative clinical diagnosis data, including the ipsilateral axillary lymph node CEUS data and peripheral blood sample; The negative-control group should comply with the pathological diagnosis, breast adenosis, fibrocystic lesions, breast cysts and other benign lesions, with complete preoperative clinical data, also including ipsilateral axillary lymph node CEUS data and peripheral blood sample

Exclusion Criteria

1. metastatic breast cancer, inflammatory breast disease, surgery without lymph node staging
2. pregnancy or lactation
3. patients with hematopoietic system disease or cancer, autoimmune diseases
4. preservation of substandard peripheral blood samples.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No